Last €369.09 EUR
Change Today +2.87 / 0.78%
Volume 192.0
RGO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 9:41 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

regeneron pharmaceuticals (RGO) Snapshot

Open
€372.00
Previous Close
€366.22
Day High
€374.75
Day Low
€355.26
52 Week High
01/23/15 - €381.00
52 Week Low
05/9/14 - €199.86
Market Cap
38.3B
Average Volume 10 Days
33.6
EPS TTM
--
Shares Outstanding
100.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REGENERON PHARMACEUTICALS (RGO)

regeneron pharmaceuticals (RGO) Details

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. The company’s trap-based clinical product candidates comprise EYLEA for the treatment of AMD and diabetic macular edema; and ZALTRAP for oncology. Its antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN727 for low-density lipoprotein cholesterol reduction and for the prevention of cardiovascular events; REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN668 for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis; REGN2222 for respiratory syncytial virus; REGN1033 for skeletal muscle disorders; and REGN2176-3 and REGN910-3 antibodies for use in ophthalmology. The company is also developing REGN1908-1909, REGN1154, REGN1500, and REGN1193 antibody product candidates; REGN1400, REGN1979, and REGN2810 for oncology; and REGN475 for the treatment of pain. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA, as well as with Avalanche Biotechnologies, Inc. to discover, develop, and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.

2,925 Employees
Last Reported Date: 02/12/15
Founded in 1988

regeneron pharmaceuticals (RGO) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $3.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $194.2K
Chief Scientific Officer, President of Regene...
Total Annual Compensation: $2.6M
Executive Vice President of Research and Deve...
Total Annual Compensation: $863.0K
Senior Vice President of Commercial
Total Annual Compensation: $814.5K
Compensation as of Fiscal Year 2013.

regeneron pharmaceuticals (RGO) Key Developments

Regeneron Pharmaceuticals, Inc. Enters into an Amended and Restated Collaboration Agreement with Sanofi-Aventis US LLC

On February 23, 2015, Regeneron Pharmaceuticals, Inc. entered into an Amended and Restated Collaboration Agreement with Sanofi-Aventis US LLC, which amended and restated the Collaboration Agreement by and between Sanofi and Regeneron dated September 5, 2003, as amended. Under the terms of the Amended Collaboration Agreement, Sanofi will be solely responsible for the development and commercialization of ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion for cancer indications worldwide. Sanofi will bear the cost of all development and commercialization activities and will reimburse Regeneron for its costs for any such activities. Sanofi will pay Regeneron a percentage of aggregate net sales of ZALTRAP during each calendar year, which percentage shall be from 15% to 30%, depending on the aggregate net sales of ZALTRAP in such calendar year. Regeneron will also be paid for all quantities of ZALTRAP manufactured by it pursuant to the Supply Agreement. Regeneron will no longer be required to reimburse Sanofi for 50% of the development expenses that Sanofi funded for the development of ZALTRAP under the Original Collaboration Agreement. Unless terminated earlier in accordance with its provisions, the Amended Collaboration Agreement will continue to be in effect until such time as neither Sanofi nor its affiliates or sublicensees is developing or commercializing ZALTRAP and such discontinuation of development and commercialization is acknowledged by both Regeneron and Sanofi to be permanent. In connection with entering into the Amended and Restated Collaboration Agreement, Regeneron and Sanofi Winthrop Industrie entered into an Amended and Restated Commercial Manufacturing and Supply Agreement for ZALTRAP pursuant to which Regeneron will manufacture and supply to SWI quantities of ZALTRAP through the earlier of 2021 or the date SWI or one of its affiliates receives regulatory approval to manufacture ZALTRAP at one of its facilities, or a facility of a third party.

Regeneron Pharmaceuticals's EYLEA (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion

Regeneron Pharmaceuticals, Inc. announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO). The new indication includes Macular Edema following Branch Retinal Vein Occlusion (BRVO) in addition to the previously approved indication of Macular Edema secondary to Central Retinal Vein Occlusion (CRVO). The recommended treatment approach in the European Union (EU) is to initiate the therapy with one injection per month, continuing monthly treatment until maximum visual acuity is achieved and/or there are no signs of disease activity. Treatment may then be continued with a treat and extend regimen with gradually increased treatment intervals to maintain stable visual and/or anatomic outcomes. EU approval is based on positive data from the Phase 3 VIBRANT study in patients with visual impairment due to macular edema secondary to BRVO. EYLEA is approved in the United States for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), which includes both CRVO and BRVO, and Diabetic Macular Edema (DME). EYLEA is also approved in the EU and other markets for use in wet AMD and DME.

Regeneron Pharmaceuticals, Inc. Announces Results from the National Institutes of Health (NIH)-Sponsored, Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Study in Patients with Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. announced that results from the National Institutes of Health (NIH)-sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T) were published in the New England Journal of Medicineand a corresponding slide set was posted online. EYLEA® (aflibercept) Injection demonstrated significantly greater improvement on the primary endpoint of mean visual acuity letter score change at one year [EYLEA +13 letters; bevacizumab (Avastin®) +10; ranibizumab (Lucentis®) +11].  These differences were driven by patients with moderate or worse vision loss at the start of the trial (worse than 20/40); in these patients, EYLEA showed a statistically significant 7-letter (approximately 1.5 lines on an eye chart) improvement over bevacizumab and a 5-letter (1 line on an eye chart) improvement over ranibizumab (EYLEA +19 letters; bevacizumab +12; ranibizumab +14). Key efficacy results at 52 weeks included: In the overall population (n=660), for the primary endpoint of mean change from baseline in best corrected visual acuity (BCVA), patients receiving EYLEA had a mean change from baseline of +13 letters. Patients treated with bevacizumab had a mean change from baseline of +10 letters (p less than 0.001, EYLEA vs. bevacizumab) and patients treated with ranibizumab had a mean change from baseline of +11 letters (p=0.03, EYLEA vs. ranibizumab); In the pre-specified group of approximately 50% of patients (n=305) with baseline visual acuity worse than 20/40, patients receiving EYLEA had a mean change from baseline in BCVA of +19 letters (almost 4 lines). Patients treated with bevacizumab had a mean change from baseline of +12 letters (almost 2.5 lines) (p less than 0.001, EYLEA vs. bevacizumab) and patients treated with ranibizumab had a mean change from baseline of +14 letters (almost 3 lines) (p equals 0.003, EYLEA vs. ranibizumab). There were no differences in visual acuity changes in those patients with baseline vision of 20/40 or better, with all groups gaining approximately 8 letters. However, even in these patients, both EYLEA and ranibizumab showed a statistically significant improvement in retinal edema, as measured by Optical Coherence Tomography (OCT) compared to bevacizumab (p less than 0.001); In the overall population, 42% of patients receiving EYLEA gained at least 15 letters (3 lines on an eye chart) in BCVA from baseline compared to 29% of patients treated with bevacizumab (p=0.03) and 32% of patients treated with ranibizumab (p=0.07); In the patients with baseline visual acuity worse than 20/40, 67% of patients receiving EYLEA gained at least 15 letters in BCVA from baseline, compared to 41% of patients treated with bevacizumab (p less than 0.001) and 50% of patients treated with ranibizumab (p=0.01). In patients with baseline visual acuity of 20/40 or better, there were no significant differences among groups; The median number of injections using the protocol-specified retreatment regimen was one fewer in patients treated with EYLEA (9 injections) compared to bevacizumab (10 injections) and ranibizumab (10 injections); Macular laser treatments could be initiated at or after the 24-week visit and repeated as often as every 13 weeks based on protocol specified criteria. Macular laser treatment was performed at least once in 36% of the patients in the EYLEA group, 56% of patients in the bevacizumab group (p less than 0.001; EYLEA vs. bevacizumab) and 46% of patients in the ranibizumab group (p = 0.058 EYLEA vs. ranibizumab).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGO:GR €369.09 EUR +2.87

RGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $181.61 USD +1.24
BioMarin Pharmaceutical Inc $107.29 USD +0.22
Kyowa Hakko Kirin Co Ltd ¥1,433 JPY -12.00
UCB SA €68.74 EUR +0.39
Vertex Pharmaceuticals Inc $118.97 USD -0.46
View Industry Companies
 

Industry Analysis

RGO

Industry Average

Valuation RGO Industry Range
Price/Earnings 100.0x
Price/Sales 14.9x
Price/Book 16.6x
Price/Cash Flow 122.0x
TEV/Sales 14.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit www.regeneron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.